BIA
ARCT icon

Bell Investment Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Bell Investment Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-38
Closed -$926 – 1886
2024
Q2 		$926 Hold
38
– – ﹤0.01% 1631
2024
Q1 		$1.28K Hold
38
– – ﹤0.01% 1524
2023
Q4 		$1.2K Hold
38
– – ﹤0.01% 1532
2023
Q3 		$971 Hold
38
– – ﹤0.01% 1584
2023
Q2 		$1.09K Hold
38
– – ﹤0.01% 1572
2023
Q1 		$911 Hold
38
– – ﹤0.01% 1610
2022
Q4 		$644 Hold
38
– – ﹤0.01% 1709
2022
Q3 		$1K Hold
38
– – ﹤0.01% 1307
2022
Q2 		$1K Buy
+38
New +$746 ﹤0.01% 1320

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bell Investment Advisors's ARCT Position: Q3 2024 in Review

Bell Investment Advisors sold out of Arcturus Therapeutics (ARCT) in Q3 2024, closing a stake of 38 shares — an estimated $926 sold.

Bell Investment Advisors first reported a position in ARCT in Q2 2022 and held it in 9 quarters. The position peaked at $1.28K in Q1 2024. 164 funds tracked by Wall St. Rank hold ARCT as of Q3 2024.

  • Bell Investment Advisors reported no remaining Arcturus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bell Investment Advisors sold 38 Arcturus Therapeutics shares in Q3 2024, an estimated $926.
  • Bell Investment Advisors first reported a position in Arcturus Therapeutics in Q2 2022 and held it in 9 quarters.
  • Bell Investment Advisors's Arcturus Therapeutics position peaked at $1.28K in Q1 2024.
  • 164 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2024.

Based on Bell Investment Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.